• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy Research and Practice >A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer
【24h】

A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

机译：授权后调查，以证明草酸铂作为南非一线化疗方案对转移性结直肠癌患者的治疗管理

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Oxaliplatin is a standard first-line treatment for metastatic colorectal cancer. The objectives were to document the therapeutic management of oxaliplatin in South Africa, determine the incidence and severity of sensory neuropathy, and record the 2-year survival rate. Meccelox was a prospective, noncontrolled, open label, multicentre, observational survey of adult patients with stage IV metastatic colorectal cancer treated with oxaliplatin-based chemotherapeutic regimens. The study was conducted from August 2007 to November 2011 in 29 sites in South Africa by 66 participating treating physicians. Among the 195 enrolled patients, 61% were treated with FOLFOX regimen (5-fluorouracil/folinic acid plus oxaliplatin) for an average of 12 cycles and 32% patients were treated with XELOX (capecitabine plus oxaliplatin) for an average of 6–8 cycles, with the main reason for discontinuation being completion of the preplanned prescribed regimen. In Meccelox survey, 80% of patients were treated with intent of palliation. Overall 64% of patients reported symptoms of sensory neuropathy. The 2-year survival rate was 30%.Conclusions. Patients received a specified preplanned number of chemotherapy cycles rather than being treated until disease progression or toxicity. Both the incidence of neuropathy and the 2-year survival rate were less than previous reports.
机译：奥沙利铂是转移性结直肠癌的标准一线治疗方法。目的是记录南非奥沙利铂的治疗管理，确定感觉神经病的发生率和严重程度，并记录2年生存率。 Meccelox是一项前瞻性，非对照，开放标签，多中心，观察性调查，研究对象是以奥沙利铂为基础的化疗方案治疗的IV期转移性结直肠癌成年患者。该研究于2007年8月至2011年11月，由66位参与治疗的医师在南非的29个地点进行。在195名登记患者中，有61％接受FOLFOX方案（5-氟尿嘧啶/亚叶酸加奥沙利铂）平均治疗12个周期，而32％接受XELOX（卡培他滨加奥沙利铂）治疗的平均6-8个周期，停药的主要原因是已完成预定的处方方案。在Meccelox调查中，有80％的患者接受了姑息治疗。总体上有64％的患者报告了感觉神经病的症状。 2年生存率为30％。结论。患者接受指定的预先计划的化疗周期数，而不是在疾病进展或毒性之前接受治疗。神经病的发生率和2年生存率均低于以前的报道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号